Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 3/20 | 0.37 |
| ▸ | CCR3 | P51677 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28026010 | 0.85 | ALDH1A1 (0.38) | CHRM2CHRM1CHRM3ATMTDP1 | |
| SCHEMBL28299375 | 0.83 | KCNA3 (0.43) | CHRM3ATM | |
| SCHEMBL28330830 | 0.83 | SLC6A4 (0.38) | CHRM3ATMHRH1CCR3KCNH2 | |
| SCHEMBL28832222 | 0.83 | TDP1 (0.51) | ATMTDP1 | |
| SCHEMBL28049321 | 0.82 | ALDH1A1 (0.40) | CHRM3ATMTDP1 | |
| SCHEMBL28073265 | 0.81 | ALDH1A1 (0.37) | CHRM2CHRM1CHRM3ATMHRH1 | |
| SCHEMBL27706054 | 0.81 | CXCR4 (0.38) | CHRM2CHRM1CHRM3CXCR4 | |
| SCHEMBL28049253 | 0.80 | LMNA (0.47) | CHRM1ATMKCNH2 | |
| SCHEMBL28086157 | 0.80 | LMNA (0.51) | ATMKCNH2 | |
| Hydrochloric Acid SCHEMBL28314858 | 0.79 | LMNA (0.54) | ATMKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947285-B | Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases | ABBVIE (US) | 2015-08-26 | — | — | CN | disclosed |